Vaxcyte, Inc.
PCVX
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -2.65% | -32.93% | 19.87% | -35.45% | 47.44% |
| Total Depreciation and Amortization | 1.86% | 6.55% | 29.13% | 12.52% | 4.85% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -18.37% | 168.45% | -25.08% | 75.11% | -39.54% |
| Change in Net Operating Assets | -1,892.56% | -108.51% | 474.90% | 89.45% | -293.97% |
| Cash from Operations | -49.26% | -83.50% | 49.99% | 23.71% | -23.53% |
| Capital Expenditure | 10.91% | 21.15% | 2.31% | -222.90% | 78.85% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 128.47% | 40.03% | -2,021.71% | 90.56% | -1,117.55% |
| Cash from Investing | 122.13% | 39.24% | -1,040.49% | 82.17% | -3,139.07% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 0.95% | -99.61% | 1,274.14% | -86.50% | 26,702.68% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -387.56% | 88.38% | -1,552.39% | 82.91% | -901.82% |
| Cash from Financing | -84.53% | -99.68% | 1,272.71% | -86.51% | 29,815.76% |
| Foreign Exchange rate Adjustments | -13.19% | 124.21% | -295.46% | -123.26% | 178.91% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 93.81% | -224.56% | 672.73% | -143.37% | 244.95% |